Acasti Pharma Inc

For the period ended Jun 30, 2024. Filed Aug 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 9, 2024

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	June 30,2024	March 31,2024
(Expressed in thousands except share data)	$	$
Assets
Current assets:
Cash and cash equivalents	19,394	23,005
Short-term investments	15	—
Receivables	398	722
Prepaid expenses	622	283
Total current assets	20,429	24,010
Equipment, net	23	24
Intangible assets	41,128	41,128
Goodwill	8,138	8,138
Total assets	69,718	73,300
Liabilities and Shareholders’ equity
Current liabilities:
Trade and other payables	2,600	1,684
Total current liabilities	2,600	1,684
Derivative warrant liabilities	2,964	4,359
Deferred tax liability	4,790	5,514
Total liabilities	10,354	11,557
Commitments and contingencies (Note 11)
Shareholders’ equity:
Class A common shares, no par value per share; unlimited shares authorized; 10,139,861 and 9,399,404 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively	261,038	261,038
Class B, C, D and E common shares, no par value per share; unlimited shares authorized; none issued and outstanding	—	—
Additional paid-in capital	18,100	17,862
Accumulated other comprehensive loss	(6,038)	(6,038)
Accumulated deficit	(213,736)	(211,119)
Total shareholders' equity	59,364	61,743
Total liabilities and shareholders’ equity	69,718	73,300

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.